title: Prehospital thrombolysis in acute myocardial infarction.
abstract: The benefit and risk of prehospital thrombolysis for acute myocardial infarction (AMI) were evaluated in a double-blind randomized trial. Patients presenting less than 4 hours after symptom onset received 2 million units of urokinase as an intravenous bolus either before (group A, n = 40) or after (group B, n = 38) hospital admission. The mean time interval from onset of symptoms to thrombolytic therapy was 85 +/- 51 minutes in group A and 137 +/- 50 minutes in group B (p less than 0.0005). In 91% of the patients, thrombolytic therapy was administered less than 3 hours after symptom onset. Complication rates during the pre- and in-hospital period were low and did not differ between groups. Three patients died (1 in group A, 2 in group B) from reinfarction 7 to 14 days after admission. Left-sided cardiac catheterization before discharge revealed a patency rate in the infarct-related artery of 61% in group A and 67% in group B (difference not significant). Global left ventricular function and regional wall motion at the infarct site did not differ significantly between group A and B (ejection fraction 51 +/- 10%, n = 28 vs 53 +/- 14%, n = 28; wall motion -2.3 +/- 1.3 vs -2.2 +/- 1.1 standard deviation, respectively). Also, peak creatine kinase did not differ significantly (838 +/- 634 U/liter in group A vs 924 +/- 595 U/liter in group B). Prehospital thrombolysis using a bolus injection of urokinase has a low risk when performed by a trained physician with a mobile care unit. The saving of 45 minutes in the early stage of an acute infarction through prehospital thrombolysis did not appear to be important for salvage of myocardial function.
authors: Universitätskrankenhaus Eppendorf, Hamburg, Federal Republic of Germany.
authors: J
authors: J
authors: Schofer
authors: J
authors: J
authors: Büttner
authors: G
authors: G
authors: Geng
authors: K
authors: K
authors: Gutschmidt
authors: H N
authors: HN
authors: Herden
authors: D G
authors: DG
authors: Mathey
authors: H P
authors: HP
authors: Moecke
authors: P
authors: P
authors: Polster
authors: A
authors: A
authors: Raftopoulo
authors: F H
authors: FH
authors: Sheehan
mesh_terms: D000552:Ambulances / Q000706:statistics & numerical data*; D017023:Coronary Angiography; D004311:Double-Blind Method; D004632:Emergency Medical Services / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D012307:Risk Factors; D015912:Thrombolytic Therapy; D013997:Time Factors; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*; D014861:Washington
chemical_list: D014568:Urokinase-Type Plasminogen Activator